BS_HD4EJYE3
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- age_years
- 11.079
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.526
- G2M_CHECKPOINT+0.468
- MYC_TARGETS_V1+0.364
- DNA_REPAIR+0.354
- SPERMATOGENESIS+0.258
- PANCREAS_BETA_CELLS+0.170
- MITOTIC_SPINDLE+0.168
- MYC_TARGETS_V2+0.079
- OXIDATIVE_PHOSPHORYLATION+0.075
- PROTEIN_SECRETION+0.056
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.674
- INTERFERON_GAMMA_RESPONSE-0.630
- INFLAMMATORY_RESPONSE-0.581
- TNFA_SIGNALING_VIA_NFKB-0.560
- IL6_JAK_STAT3_SIGNALING-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.519
- ALLOGRAFT_REJECTION-0.511
- ANGIOGENESIS-0.493
- IL2_STAT5_SIGNALING-0.475
- HYPOXIA-0.471
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_GNV89A5P | medulloblastoma | — | 0.992 |
| 2 | BS_J8G4SH4Z | medulloblastoma | — | 0.990 |
| 3 | BS_HF3RNN2T | medulloblastoma | — | 0.989 |
| 4 | BS_Y8D1F5WW | medulloblastoma | — | 0.988 |
| 5 | BS_DFWFBYSN | medulloblastoma | — | 0.986 |
| 6 | BS_4PH1MBGR | medulloblastoma | — | 0.984 |
| 7 | BS_4CP4T22V | medulloblastoma | — | 0.984 |
| 8 | BS_QPPPGYP4 | medulloblastoma | — | 0.982 |
| 9 | BS_G00FHF3Q | medulloblastoma | — | 0.981 |
| 10 | BS_HTEPAKCM | medulloblastoma | — | 0.981 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.526 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.468 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.364 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.354 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.258 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.168 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.079 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.075 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.056 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.013 | Inavolisib | — uncovered |